
Outpatient Oncology Infusion Market - forecast to 2033 : By CANCER TYPE (Breast Cancer, Colorectal Cancer, Prostate Cancer, Hematologic, Others), THERAPY TYPES (Immunotherapy), MODE (Subcutaneous), TREATMENT SETTING (Hospital-Based Outpatient Centers, Sta
Description
Outpatient Oncology Infusion Market - forecast to 2033 : By CANCER TYPE (Breast Cancer, Colorectal Cancer, Prostate Cancer, Hematologic, Others), THERAPY TYPES (Immunotherapy), MODE (Subcutaneous), TREATMENT SETTING (Hospital-Based Outpatient Centers, Standalone Cancer Treatment Centers, Physician Offices, Ambulatory Infusion Centers), INFUSION TYPE (Chemotherapy Infusions, Targeted Therapy Infusions, Supportive Care Medications), PROVIDER TYPE (Academic Medical Centers, Community Hospitals, Specialty Clinic), and Region
The Outpatient Oncology Infusion Market refers to the sector that encompasses the provision of cancer treatment services, specifically chemotherapy and other drug infusions, in an outpatient setting. This market is characterized by the delivery of care outside of a traditional hospital environment, often in specialized clinics or treatment centers.
The Outpatient Oncology Infusion Market Market size was USD 70.39 Billion in 2023, and it is anticipated to grow to over 217.28 Billion by 2033, at a CAGR of over 11.9% during the forecast period.
The outpatient oncology infusion services market is driven by several key factors, including the rising prevalence of cancer, ongoing advancements in cancer treatments, and an increasing preference for outpatient care due to its cost-effectiveness and patient-centric approach. This market thrives on its emphasis on patient comfort and convenience, providing effective treatments such as chemotherapy, immunotherapy, hormone therapy, and targeted therapy, while allowing patients to return home the same day. Additionally, the focus on continuous innovation in treatment methods and technologies, coupled with personalized medicine and supportive care services like pain management and nutritional support, further propels the growth of outpatient oncology infusion services..
Key Trends:
- Shift towards Personalized Treatment: Increasing focus on personalized cancer therapies tailored to individual patient's genetic makeup.
- Adoption of Immuno-Oncology Therapies: Rising use of immuno-oncology therapies that stimulate the body's immune system to fight cancer
- Technological Advancements in Infusion Devices: Development of smarter and more efficient infusion devices for outpatient settings.
- Increased Use of Biosimilars: Growing adoption of biosimilars due to their cost-effectiveness and similar efficacy to original biologic drugs.
- Emphasis on Home-Based Care: Shift towards home-based oncology infusion treatments for patient comfort and convenience.
- Aging Population: The increasing number of elderly people globally who are more susceptible to cancer.
- Advances in Cancer Treatment: The development of innovative and effective oncology drugs and therapies.
- Cost-Effectiveness: Outpatient oncology infusion services are often less expensive than inpatient care, making it a preferred choice for many.
- Convenience and Comfort: Outpatient services allow patients to receive treatment in a more comfortable environment and maintain their regular routine.
- Rise in Cancer Prevalence: The increasing incidence of various types of cancer worldwide is driving the demand for outpatient oncology infusion services.
- High Treatment Costs: The high cost of cancer treatment can be a significant barrier for many patients, limiting market growth.
- Lack of Skilled Healthcare Professionals: The shortage of trained healthcare professionals in oncology can hinder the delivery of outpatient infusion services.
- Regulatory Challenges: Strict regulations and guidelines related to the administration of chemotherapy drugs can pose challenges.
- Reimbursement Issues: Inadequate reimbursement policies can deter patients from opting for outpatient oncology infusion services.
- Infrastructure Limitations: In developing regions, lack of proper healthcare infrastructure can restrict the growth of the outpatient oncology infusion market..
Cancer Type (Breast Cancer, Colorectal Cancer, Prostate Cancer, Hematologic, Others), Therapy Types (Immunotherapy), Mode (Subcutaneous), Treatment Setting (Hospital-Based Outpatient Centers, Standalone Cancer Treatment Centers, Physician Offices, Ambulatory Infusion Centers), Infusion Type (Chemotherapy Infusions, Targeted Therapy Infusions, Supportive Care Medications), Provider Type (Academic Medical Centers, Community Hospitals, Specialty Clinic), And Region
Key Players:
The Outpatient Oncology Infusion Market includes players such as Roche, Novartis, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Merck & Co, Amgen, Celgene, Eli Lilly, AstraZeneca, Sanofi, Bayer, Takeda Pharmaceutical, Gilead Sciences, AbbVie, GlaxoSmithKline, Teva Pharmaceutical, Astellas Pharma, Daiichi Sankyo, and Boehringer Ingelheim, among others.
Value Chain Analysis:
The value chain analysis for the Outpatient Oncology Infusion Market spans across five critical stages: Raw Material Procurement, R&D, Product Approval, Large Scale Manufacturing, and Sales and Marketing. Each stage plays a pivotal role in ensuring the successful delivery of oncology infusion products to the market. Below is a detailed examination of each stage:
- Raw Material Procurement: Identify sources of raw materials, assess their availability, quality, and sustainability. Understanding market dynamics, pricing trends, and potential risks associated with sourcing materials is crucial. This stage involves establishing strong relationships with suppliers, ensuring compliance with regulatory standards, and implementing robust quality control measures to guarantee the integrity of raw materials used in oncology infusion products.
- R&D: Focuses on market analysis, trend forecasting, feasibility studies, and conducting experiments to develop new products or enhance existing ones. In the context of outpatient oncology infusion, R&D efforts are directed towards innovating drug formulations, improving delivery mechanisms, and ensuring patient safety and comfort. Collaboration with academic institutions, clinical trials, and leveraging advanced technologies such as bioinformatics and genomics are integral components of this stage.
- Product Approval: Understanding legal requirements, industry regulations, and certification processes, testing products for safety, efficacy, and environmental impact. This stage involves rigorous clinical trials, submission of comprehensive data to regulatory bodies such as the FDA or EMA, and obtaining necessary approvals. Ensuring adherence to Good Manufacturing Practices (GMP) and maintaining transparency in reporting are critical to gaining regulatory approval and establishing trust with stakeholders.
- Large Scale Manufacturing: Optimizing production processes, improving efficiency, and reducing costs. This stage encompasses process engineering, automation technologies, and supply chain management to enhance productivity and quality. In the oncology infusion market, it is imperative to maintain stringent quality control measures, ensure sterile manufacturing environments, and implement robust logistics to handle the sensitive nature of the products. Scalability and flexibility in manufacturing processes are essential to meet varying demand levels and regulatory requirements.
- Sales and Marketing: Understanding customer needs, market trends, and competitive landscape, market segmentation, consumer behavior analysis, and branding strategies. This stage involves developing targeted marketing campaigns, educating healthcare providers and patients about the benefits of the oncology infusion products, and establishing strong distribution networks. Utilizing digital marketing, attending industry conferences, and building partnerships with healthcare institutions are effective strategies to enhance market penetration and drive sales growth.
- Estimates and forecast the overall market size for the total market, across type, application, and region
- Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling
- Identify factors influencing market growth and challenges, opportunities, drivers, and restraints
- Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates
- Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities
- Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market
- To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements
- Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
350 Pages
- 1.0: MARKET DEFINITION
- 1.1: MARKET SEGMENTATION
- 1.2: REGIONAL COVERAGE
- 1.3: KEY COMPANY PROFILES
- 1.4: DATA SNAPSHOT
- 2.0: SUMMARY
- 2.1: KEY OPINION LEADERS
- 2.2: KEY HIGHLIGHTS BY CANCER TYPE
- 2.3: KEY HIGHLIGHTS BY THERAPY TYPES
- 2.4: KEY HIGHLIGHTS BY MODE
- 2.5: KEY HIGHLIGHTS BY TREATMENT SETTING
- 2.6: KEY HIGHLIGHTS BY INFUSION TYPE
- 2.7: KEY HIGHLIGHTS BY PROVIDER TYPE
- 2.8: KEY HIGHLIGHTS BY REGION
- 2.9: KEY HIGHLIGHTS BY COUNTRY
- 2.10: KEY HIGHLIGHTS BY COUNTRY
- 2.11: KEY HIGHLIGHTS BY COUNTRY
- 2.12: KEY HIGHLIGHTS BY COUNTRY
- 2.13: KEY HIGHLIGHTS BY COUNTRY
- 3.0: MARKET ATTRACTIVENESS ANALYSIS BY CANCER TYPE
- 3.1: MARKET ATTRACTIVENESS ANALYSIS BY THERAPY TYPES
- 3.2: MARKET ATTRACTIVENESS ANALYSIS BY MODE
- 3.3: MARKET ATTRACTIVENESS ANALYSIS BY TREATMENT SETTING
- 3.4: MARKET ATTRACTIVENESS ANALYSIS BY INFUSION TYPE
- 3.5: MARKET ATTRACTIVENESS ANALYSIS BY PROVIDER TYPE
- 3.6: MARKET ATTRACTIVENESS ANALYSIS BY REGION
- 3.7: MARKET ATTRACTIVENESS ANALYSIS BY COUNTRY
- 4.0: MARKET TRENDS
- 4.1: MARKET DRIVERS
- 4.2: MARKET OPPORTUNITIES
- 4.3: MARKET RESTRAINTS
- 4.4: MARKET THREATS
- 4.5: IMPACT ANALYSIS
- 5.0: PORTERS FIVE FORCES
- 5.1: ANSOFF MATRIX
- 5.2: PESTLE ANALYSIS
- 5.3: VALUE CHAIN ANALYSIS
- 6.0: IMPACT OF COVID-19 ON MARKET
- 7.0: IMPACT OF RUSSIA-UKRAINE WAR
- 8.0: PARENT MARKET ANALYSIS
- 8.1: REGULATORY LANDSCAPE
- 8.2: PRICING ANALYSIS
- 8.3: DEMAND SUPPLY ANALYSIS
- 8.4: DEMAND SUPPLY ANALYSIS
- 8.5: CONSUMER BUYING INTEREST
- 8.6: CONSUMER BUYING INTEREST
- 8.7: SUPPLY CHAIN ANALYSIS
- 8.8: COMPETITION PRODUCT ANALYSIS BY MANUFACTURER
- 8.9: TECHNOLOGICAL ADVANCEMENTS
- 8.10: RECENT DEVELOPMENTS
- 8.11: CASE STUDIES
- 9.0: MARKET SIZE AND FORECAST – BY VALUE
- 9.1: MARKET SIZE AND FORECAST – BY VOLUME
- 10.0: CANCER TYPE OVERVIEW
- 10.1: MARKET SIZE AND FORECAST – BY CANCER TYPE
- 10.2: BREAST CANCER OVERVIEW
- 10.3: BREAST CANCER BY REGION
- 10.4: BREAST CANCER BY COUNTRY
- 10.5: COLORECTAL CANCER OVERVIEW
- 10.6: COLORECTAL CANCER BY REGION
- 10.7: COLORECTAL CANCER BY COUNTRY
- 10.8: PROSTATE CANCER OVERVIEW
- 10.9: PROSTATE CANCER BY REGION
- 10.10: PROSTATE CANCER BY COUNTRY
- 10.11: HEMATOLOGIC OVERVIEW
- 10.12: HEMATOLOGIC BY REGION
- 10.13: HEMATOLOGIC BY COUNTRY
- 10.14: OTHERS OVERVIEW
- 10.15: OTHERS BY REGION
- 10.16: OTHERS BY COUNTRY
- 11.0: THERAPY TYPES OVERVIEW
- 11.1: MARKET SIZE AND FORECAST – BY THERAPY TYPES
- 11.2: IMMUNOTHERAPY OVERVIEW
- 11.3: IMMUNOTHERAPY BY REGION
- 11.4: IMMUNOTHERAPY BY COUNTRY
- 12.0: MODE OVERVIEW
- 12.1: MARKET SIZE AND FORECAST – BY MODE
- 12.2: SUBCUTANEOUS OVERVIEW
- 12.3: SUBCUTANEOUS BY REGION
- 12.4: SUBCUTANEOUS BY COUNTRY
- 13.0: TREATMENT SETTING OVERVIEW
- 13.1: MARKET SIZE AND FORECAST – BY TREATMENT SETTING
- 13.2: HOSPITAL-BASED OUTPATIENT CENTERS OVERVIEW
- 13.3: HOSPITAL-BASED OUTPATIENT CENTERS BY REGION
- 13.4: HOSPITAL-BASED OUTPATIENT CENTERS BY COUNTRY
- 13.5: STANDALONE CANCER TREATMENT CENTERS OVERVIEW
- 13.6: STANDALONE CANCER TREATMENT CENTERS BY REGION
- 13.7: STANDALONE CANCER TREATMENT CENTERS BY COUNTRY
- 13.8: PHYSICIAN OFFICES OVERVIEW
- 13.9: PHYSICIAN OFFICES BY REGION
- 13.10: PHYSICIAN OFFICES BY COUNTRY
- 13.11: AMBULATORY INFUSION CENTERS OVERVIEW
- 13.12: AMBULATORY INFUSION CENTERS BY REGION
- 13.13: AMBULATORY INFUSION CENTERS BY COUNTRY
- 14.0: INFUSION TYPE OVERVIEW
- 14.1: MARKET SIZE AND FORECAST – BY INFUSION TYPE
- 14.2: CHEMOTHERAPY INFUSIONS OVERVIEW
- 14.3: CHEMOTHERAPY INFUSIONS BY REGION
- 14.4: CHEMOTHERAPY INFUSIONS BY COUNTRY
- 14.5: TARGETED THERAPY INFUSIONS OVERVIEW
- 14.6: TARGETED THERAPY INFUSIONS BY REGION
- 14.7: TARGETED THERAPY INFUSIONS BY COUNTRY
- 14.8: SUPPORTIVE CARE MEDICATIONS OVERVIEW
- 14.9: SUPPORTIVE CARE MEDICATIONS BY REGION
- 14.10: SUPPORTIVE CARE MEDICATIONS BY COUNTRY
- 15.0: PROVIDER TYPE OVERVIEW
- 15.1: MARKET SIZE AND FORECAST – BY PROVIDER TYPE
- 15.2: ACADEMIC MEDICAL CENTERS OVERVIEW
- 15.3: ACADEMIC MEDICAL CENTERS BY REGION
- 15.4: ACADEMIC MEDICAL CENTERS BY COUNTRY
- 15.5: COMMUNITY HOSPITALS OVERVIEW
- 15.6: COMMUNITY HOSPITALS BY REGION
- 15.7: COMMUNITY HOSPITALS BY COUNTRY
- 15.8: SPECIALTY CLINIC OVERVIEW
- 15.9: SPECIALTY CLINIC BY REGION
- 15.10: SPECIALTY CLINIC BY COUNTRY
- 16.0: REGION OVERVIEW
- 16.1: MARKET SIZE AND FORECAST - BY REGION
- 16.2: NORTH AMERICA OVERVIEW
- 16.3: NORTH AMERICA BY COUNTRY
- 16.4: UNITED STATES OVERVIEW
- 16.5: UNITED STATES OVERVIEW
- 16.6: UNITED STATES OVERVIEW
- 16.7: UNITED STATES OVERVIEW
- 16.8: UNITED STATES OVERVIEW
- 16.9: UNITED STATES OVERVIEW
- 16.10: UNITED STATES OVERVIEW
- 16.11: CANADA OVERVIEW
- 16.12: CANADA OVERVIEW
- 16.13: CANADA OVERVIEW
- 16.14: CANADA OVERVIEW
- 16.15: CANADA OVERVIEW
- 16.16: CANADA OVERVIEW
- 16.17: CANADA OVERVIEW
- 16.18: LATIN AMERICA OVERVIEW
- 16.19: LATIN AMERICA BY COUNTRY
- 16.20: MEXICO OVERVIEW
- 16.21: MEXICO OVERVIEW
- 16.22: MEXICO OVERVIEW
- 16.23: MEXICO OVERVIEW
- 16.24: MEXICO OVERVIEW
- 16.25: MEXICO OVERVIEW
- 16.26: MEXICO OVERVIEW
- 16.27: BRAZIL OVERVIEW
- 16.28: BRAZIL OVERVIEW
- 16.29: BRAZIL OVERVIEW
- 16.30: BRAZIL OVERVIEW
- 16.31: BRAZIL OVERVIEW
- 16.32: BRAZIL OVERVIEW
- 16.33: BRAZIL OVERVIEW
- 16.34: ARGENTINA OVERVIEW
- 16.35: ARGENTINA OVERVIEW
- 16.36: ARGENTINA OVERVIEW
- 16.37: ARGENTINA OVERVIEW
- 16.38: ARGENTINA OVERVIEW
- 16.39: ARGENTINA OVERVIEW
- 16.40: ARGENTINA OVERVIEW
- 16.41: REST OF LATAM OVERVIEW
- 16.42: REST OF LATAM OVERVIEW
- 16.43: REST OF LATAM OVERVIEW
- 16.44: REST OF LATAM OVERVIEW
- 16.45: REST OF LATAM OVERVIEW
- 16.46: REST OF LATAM OVERVIEW
- 16.47: EUROPE OVERVIEW
- 16.48: EUROPE BY COUNTRY
- 16.49: FRANCE OVERVIEW
- 16.50: FRANCE OVERVIEW
- 16.51: FRANCE OVERVIEW
- 16.52: FRANCE OVERVIEW
- 16.53: FRANCE OVERVIEW
- 16.54: FRANCE OVERVIEW
- 16.55: FRANCE OVERVIEW
- 16.56: UNITED KINGDOM OVERVIEW
- 16.57: UNITED KINGDOM OVERVIEW
- 16.58: UNITED KINGDOM OVERVIEW
- 16.59: UNITED KINGDOM OVERVIEW
- 16.60: UNITED KINGDOM OVERVIEW
- 16.61: UNITED KINGDOM OVERVIEW
- 16.62: UNITED KINGDOM OVERVIEW
- 16.63: RUSSIA OVERVIEW
- 16.64: RUSSIA OVERVIEW
- 16.65: RUSSIA OVERVIEW
- 16.66: RUSSIA OVERVIEW
- 16.67: RUSSIA OVERVIEW
- 16.68: RUSSIA OVERVIEW
- 16.69: RUSSIA OVERVIEW
- 16.70: SPAIN OVERVIEW
- 16.71: SPAIN OVERVIEW
- 16.72: SPAIN OVERVIEW
- 16.73: SPAIN OVERVIEW
- 16.74: SPAIN OVERVIEW
- 16.75: SPAIN OVERVIEW
- 16.76: SPAIN OVERVIEW
- 16.77: ITALY OVERVIEW
- 16.78: ITALY OVERVIEW
- 16.79: ITALY OVERVIEW
- 16.80: ITALY OVERVIEW
- 16.81: ITALY OVERVIEW
- 16.82: ITALY OVERVIEW
- 16.83: ITALY OVERVIEW
- 16.84: NETHERLANDS OVERVIEW
- 16.85: NETHERLANDS OVERVIEW
- 16.86: NETHERLANDS OVERVIEW
- 16.87: NETHERLANDS OVERVIEW
- 16.88: NETHERLANDS OVERVIEW
- 16.89: NETHERLANDS OVERVIEW
- 16.90: NETHERLANDS OVERVIEW
- 16.91: ISRAEL OVERVIEW
- 16.92: ISRAEL OVERVIEW
- 16.93: ISRAEL OVERVIEW
- 16.94: ISRAEL OVERVIEW
- 16.95: ISRAEL OVERVIEW
- 16.96: ISRAEL OVERVIEW
- 16.97: ISRAEL OVERVIEW
- 16.98: TURKEY OVERVIEW
- 16.99: TURKEY OVERVIEW
- 16.100: TURKEY OVERVIEW
- 16.101: TURKEY OVERVIEW
- 16.102: TURKEY OVERVIEW
- 16.103: TURKEY OVERVIEW
- 16.104: TURKEY OVERVIEW
- 16.105: REST OF EUROPE OVERVIEW
- 16.106: REST OF EUROPE OVERVIEW
- 16.107: REST OF EUROPE OVERVIEW
- 16.108: REST OF EUROPE OVERVIEW
- 16.109: REST OF EUROPE OVERVIEW
- 16.110: REST OF EUROPE OVERVIEW
- 16.111: ASIA/PACIFIC OVERVIEW
- 16.112: ASIA/PACIFIC BY COUNTRY
- 16.113: CHINA OVERVIEW
- 16.114: CHINA OVERVIEW
- 16.115: CHINA OVERVIEW
- 16.116: CHINA OVERVIEW
- 16.117: CHINA OVERVIEW
- 16.118: CHINA OVERVIEW
- 16.119: CHINA OVERVIEW
- 16.120: INDIA OVERVIEW
- 16.121: INDIA OVERVIEW
- 16.122: INDIA OVERVIEW
- 16.123: INDIA OVERVIEW
- 16.124: INDIA OVERVIEW
- 16.125: INDIA OVERVIEW
- 16.126: INDIA OVERVIEW
- 16.127: JAPAN OVERVIEW
- 16.128: JAPAN OVERVIEW
- 16.129: JAPAN OVERVIEW
- 16.130: JAPAN OVERVIEW
- 16.131: JAPAN OVERVIEW
- 16.132: JAPAN OVERVIEW
- 16.133: JAPAN OVERVIEW
- 16.134: AUSTRALIA OVERVIEW
- 16.135: AUSTRALIA OVERVIEW
- 16.136: AUSTRALIA OVERVIEW
- 16.137: AUSTRALIA OVERVIEW
- 16.138: AUSTRALIA OVERVIEW
- 16.139: AUSTRALIA OVERVIEW
- 16.140: AUSTRALIA OVERVIEW
- 16.141: INDONESIA OVERVIEW
- 16.142: INDONESIA OVERVIEW
- 16.143: INDONESIA OVERVIEW
- 16.144: INDONESIA OVERVIEW
- 16.145: INDONESIA OVERVIEW
- 16.146: INDONESIA OVERVIEW
- 16.147: INDONESIA OVERVIEW
- 16.148: MALAYSIA OVERVIEW
- 16.149: MALAYSIA OVERVIEW
- 16.150: MALAYSIA OVERVIEW
- 16.151: MALAYSIA OVERVIEW
- 16.152: MALAYSIA OVERVIEW
- 16.153: MALAYSIA OVERVIEW
- 16.154: MALAYSIA OVERVIEW
- 16.155: REST OF APAC OVERVIEW
- 16.156: REST OF APAC OVERVIEW
- 16.157: REST OF APAC OVERVIEW
- 16.158: REST OF APAC OVERVIEW
- 16.159: REST OF APAC OVERVIEW
- 16.160: REST OF APAC OVERVIEW
- 16.161: MIDDLE EAST/AFRICA OVERVIEW
- 16.162: MIDDLE EAST/AFRICA BY COUNTRY
- 16.163: SAUDI ARABIA OVERVIEW
- 16.164: SAUDI ARABIA OVERVIEW
- 16.165: SAUDI ARABIA OVERVIEW
- 16.166: SAUDI ARABIA OVERVIEW
- 16.167: SAUDI ARABIA OVERVIEW
- 16.168: SAUDI ARABIA OVERVIEW
- 16.169: SAUDI ARABIA OVERVIEW
- 16.170: UAE OVERVIEW
- 16.171: UAE OVERVIEW
- 16.172: UAE OVERVIEW
- 16.173: UAE OVERVIEW
- 16.174: UAE OVERVIEW
- 16.175: UAE OVERVIEW
- 16.176: UAE OVERVIEW
- 16.177: SOUTH AFRICA OVERVIEW
- 16.178: SOUTH AFRICA OVERVIEW
- 16.179: SOUTH AFRICA OVERVIEW
- 16.180: SOUTH AFRICA OVERVIEW
- 16.181: SOUTH AFRICA OVERVIEW
- 16.182: SOUTH AFRICA OVERVIEW
- 16.183: SOUTH AFRICA OVERVIEW
- 16.184: IRAN OVERVIEW
- 16.185: IRAN OVERVIEW
- 16.186: IRAN OVERVIEW
- 16.187: IRAN OVERVIEW
- 16.188: IRAN OVERVIEW
- 16.189: IRAN OVERVIEW
- 16.190: IRAN OVERVIEW
- 16.191: QATAR OVERVIEW
- 16.192: QATAR OVERVIEW
- 16.193: QATAR OVERVIEW
- 16.194: QATAR OVERVIEW
- 16.195: QATAR OVERVIEW
- 16.196: QATAR OVERVIEW
- 16.197: QATAR OVERVIEW
- 16.198: REST OF MEA OVERVIEW
- 16.199: REST OF MEA OVERVIEW
- 16.200: REST OF MEA OVERVIEW
- 16.201: REST OF MEA OVERVIEW
- 16.202: REST OF MEA OVERVIEW
- 16.203: REST OF MEA OVERVIEW
- 17.0: COMPETITION OVERVIEW
- 17.1: MARKET SHARE ANALYSIS
- 17.2: MARKET REVENUE BY KEY COMPANIES
- 17.3: MARKET POSITIONING
- 17.4: VENDORS BENCHMARKING
- 17.5: STRATEGY BENCHMARKING
- 17.6: STRATEGY BENCHMARKING
- 18.0: Roche
- 18.1: Roche
- 18.2: Roche
- 18.3: Roche
- 18.4: Roche
- 18.5: Novartis
- 18.6: Novartis
- 18.7: Novartis
- 18.8: Novartis
- 18.9: Novartis
- 18.10: Johnson & Johnson
- 18.11: Johnson & Johnson
- 18.12: Johnson & Johnson
- 18.13: Johnson & Johnson
- 18.14: Johnson & Johnson
- 18.15: Pfizer
- 18.16: Pfizer
- 18.17: Pfizer
- 18.18: Pfizer
- 18.19: Pfizer
- 18.20: Bristol-Myers Squibb
- 18.21: Bristol-Myers Squibb
- 18.22: Bristol-Myers Squibb
- 18.23: Bristol-Myers Squibb
- 18.24: Bristol-Myers Squibb
- 18.25: Merck & Co
- 18.26: Merck & Co
- 18.27: Merck & Co
- 18.28: Merck & Co
- 18.29: Merck & Co
- 18.30: Amgen
- 18.31: Amgen
- 18.32: Amgen
- 18.33: Amgen
- 18.34: Amgen
- 18.35: Celgene
- 18.36: Celgene
- 18.37: Celgene
- 18.38: Celgene
- 18.39: Celgene
- 18.40: Eli Lilly
- 18.41: Eli Lilly
- 18.42: Eli Lilly
- 18.43: Eli Lilly
- 18.44: Eli Lilly
- 18.45: AstraZeneca
- 18.46: AstraZeneca
- 18.47: AstraZeneca
- 18.48: AstraZeneca
- 18.49: AstraZeneca
- 18.50: Sanofi
- 18.51: Sanofi
- 18.52: Sanofi
- 18.53: Sanofi
- 18.54: Sanofi
- 18.55: Bayer
- 18.56: Bayer
- 18.57: Bayer
- 18.58: Bayer
- 18.59: Bayer
- 18.60: Takeda Pharmaceutical
- 18.61: Takeda Pharmaceutical
- 18.62: Takeda Pharmaceutical
- 18.63: Takeda Pharmaceutical
- 18.64: Takeda Pharmaceutical
- 18.65: Gilead Sciences
- 18.66: Gilead Sciences
- 18.67: Gilead Sciences
- 18.68: Gilead Sciences
- 18.69: Gilead Sciences
- 18.70: AbbVie
- 18.71: AbbVie
- 18.72: AbbVie
- 18.73: AbbVie
- 18.74: AbbVie
- 18.75: GlaxoSmithKline
- 18.76: GlaxoSmithKline
- 18.77: GlaxoSmithKline
- 18.78: GlaxoSmithKline
- 18.79: GlaxoSmithKline
- 18.80: Teva Pharmaceutical
- 18.81: Teva Pharmaceutical
- 18.82: Teva Pharmaceutical
- 18.83: Teva Pharmaceutical
- 18.84: Teva Pharmaceutical
- 18.85: Astellas Pharma
- 18.86: Astellas Pharma
- 18.87: Astellas Pharma
- 18.88: Astellas Pharma
- 18.89: Astellas Pharma
- 18.90: Daiichi Sankyo
- 18.91: Daiichi Sankyo
- 18.92: Daiichi Sankyo
- 18.93: Daiichi Sankyo
- 18.94: Daiichi Sankyo
- 18.95: Boehringer Ingelheim
- 18.96: Boehringer Ingelheim
- 18.97: Boehringer Ingelheim
- 18.98: Boehringer Ingelheim
- 18.99: Boehringer Ingelheim
- 475})
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.